| Symbol
| AGER
| contributors: mct - updated : 18-06-2015
|
| HGNC name
| advanced glycosylation end product-specific receptor
|
| HGNC id
| 320
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
| |
in cerebral vasculature of Alzheimer's disease patients | | constitutional
|
|
| --over
|
| |
increased in preeclampsia (Fasshauer 2008) | | constitutional
|
|
| --over
|
| |
in patients with pulmonary tuberculosis as well as in diabetics | | constitutional
|
|
|
| gain of function
|
implicated in numerous pathological states including vascular disease, diabetes, cancer, and neurodegeneration  | |
| Susceptibility
|
to type 1 diabetes |
| Variant & Polymorphism
SNP
, other
| -374 T/A polymorphism associated to type 1 diabetes |
| 
|
Candidate gene
| Marker
| CCNB2, AGER, CDK5RAP3, may be used as a very reliable biomarker of lung adenocarcinoma | |
mRNA expression of S100A12 and AGER might be as a useful biomarker for Transitional cell carcinoma (TCC) | |
| Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| miscelleaneous | vascular | | |
| therapeutic intervention targeted at the AGER gene may be a useful means of treating pathologies of the vasculature | | neurology | neurodegenerative | alzheimer | |
| pharmacological stimulation of AGER shedding might open alternative treatment strategies for Alzheimer disease | | diabete | | | |
| pharmacological stimulation of AGER shedding might open alternative treatment strategies for diabetes-induced inflammation | | cardiovascular | aquired | | |
| therapeutic antagonism of RAGE might be a unique target for therapeutic intervention in heart failure |
| | |
|
| Rage-deficient mice displayed a reduced propensity for breast tumor growth |